About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) specializes in developing therapies based on RNA interference (RNAi), a groundbreaking approach in gene silencing that targets the root cause of diseases at the genetic level. Its operations are deeply entrenched in the discovery, development, and commercialization of RNAi therapeutics for patients with rare genetic diseases and other conditions with limited treatment options. Among its projects, Alnylam has successfully brought several drugs to market and has a rich pipeline focusing on genetic medicines, liver diseases, and cardiovascular health. The company's objective is to harness the power of RNAi to address diseases that have been historically difficult to treat through conventional methods, aiming to make significant contributions to medical science and patient care.
Snapshot
Operations
Products and/or services of Alnylam Pharmaceuticals
- ONPATTRO (patisiran), for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
- GIVLAARI (givosiran), addressing acute hepatic porphyria (AHP) in adults.
- OXLUMO (lumasiran), designed for primary hyperoxaluria type 1 (PH1) in all ages.
- Leqvio (inclisiran), developed for hypercholesterolemia or mixed dyslipidemia, in collaboration with Novartis.
- VUTRISIRAN, an investigational therapy for hATTR amyloidosis, offering a dosing regimen of once every three months.
- AMVUTTRA (vutrisiran), aimed at treating polyneuropathy of hATTR amyloidosis in adults.
Alnylam Pharmaceuticals executive team
- Dr. Yvonne L. Greenstreet M.B.A., M.D.CEO & Director
- Dr. Phillip A. Sharp Ph.D.Co-Founder, Member of the Scientific Advisory Board
- Mr. Jeffrey V. Poulton M.B.A.CFO & Executive VP
- Dr. Kevin Joseph Fitzgerald Ph.D.Executive VP, Chief Scientific Officer and Head of Early Research & Early Development
- Dr. Pushkal P. Garg M.D.EVP of Development & Medical Affairs and Chief Research & Dev. Officer
- Mr. Tolga Tanguler M.B.A.Executive VP & Chief Commercial Officer
- Mr. Timothy J. MainesChief Technical Operations & Quality Officer
- Mr. Piyush Sharma J.D.Chief Ethics & Compliance Officer
- Mr. Bryan Andrew Supran J.D.Chief Legal Officer
- Ms. Christine Regan AkincChief Corporate Communications Officer